Viewing Study NCT02614833


Ignite Creation Date: 2025-12-25 @ 2:45 AM
Ignite Modification Date: 2026-03-06 @ 10:10 PM
Study NCT ID: NCT02614833
Status: COMPLETED
Last Update Posted: 2021-10-05
First Post: 2015-11-05
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma
Sponsor: Immutep S.A.S.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module